Regulatory
Published · Updated · 1 min read
EMA: negative benefit–risk assessment of palbociclib maintenance for HR+/HER2+ metastatic breast cancer
What it means for practice
For the proposed maintenance treatment of HR+/HER2+ metastatic breast cancer, consider that despite improved progression-free survival, the benefit–risk assessment was negative because efficacy evidence was insufficiently robust.
Summary
According to the supplied summary of the EMA report on Ibrance (palbociclib), the assessment concerned its proposed use with anti-HER2 and endocrine therapies for maintenance treatment of hormone receptor-positive, HER2-positive metastatic breast cancer. The document is titled a withdrawal assessment report.
Efficacy and concerns
The phase III PATINA study showed a statistically significant improvement in progression-free survival with palbociclib. However, the assessment raised concerns about potential investigator bias and censoring. These issues limited the robustness of efficacy conclusions; statistical significance did not resolve the regulatory concerns.
Safety and overall assessment
The safety profile was consistent with the known effects of palbociclib, including increased neutropenia and infections. The overall benefit–risk balance for the proposed use was considered negative because the efficacy evidence was insufficiently robust. Thus, the key limitation was uncertainty about the reliability of the efficacy results, despite the statistically significant improvement in progression-free survival.
Source
-
EMA. Withdrawal assessment report for Ibrance (VR-0000316536) Adopted.
Reviewed by: DrugCard editorial team ·
This article does not replace clinical judgement. Disclaimer
